Asparaginase erwinia chrysanthemi-rywn (Rylaze)
Note: this is a recombinant product which is essentially identical to Asparaginase Erwinia chrysanthemi (Erwinaze). It is not a biosimilar.
General information
Class/mechanism: Depletes plasma asparagine by catalyzing the deamidation of asparagine to
aspartic acid and ammonia, selectively killing leukemic cells which are unable to synthesize asparagine due to a lack of asparagine synthetase.
Route: IM
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
History of changes in FDA indication
- 2021-06-30: Approved as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase. (Based on JZP458-201)
- 2022-11-18: Approved a new Monday-Wednesday-Friday dosing regimen. Under the new regimen, patients should receive 25 mg/m2 intramuscularly on Monday and Wednesday mornings, and 50 mg/m2 intramuscularly on Friday afternoon. (Based on JZP458-201)
Also known as
- Generic names: recombinant crisantaspasum, recombinant crisantaspase, recombinant Erwinia L-asparginase, recombinant krisantaspaasi, recombinant krisantaspas
- Brand names: Rylaze